MA39927A - Inhibiteurs de glyt1 pour le traitement de troubles hématologiques - Google Patents
Inhibiteurs de glyt1 pour le traitement de troubles hématologiquesInfo
- Publication number
- MA39927A MA39927A MA039927A MA39927A MA39927A MA 39927 A MA39927 A MA 39927A MA 039927 A MA039927 A MA 039927A MA 39927 A MA39927 A MA 39927A MA 39927 A MA39927 A MA 39927A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- blood disorders
- glyt1 inhibitors
- glyt1
- inhibitors
- Prior art date
Links
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 title 1
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166497 | 2014-04-30 | ||
| EP15717916.9A EP3137073B1 (fr) | 2014-04-30 | 2015-04-27 | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques |
| PCT/EP2015/059037 WO2015165842A1 (fr) | 2014-04-30 | 2015-04-27 | Inhibiteurs de glyt1 destinés à être utilisés dans le traitement de troubles hématologiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39927A true MA39927A (fr) | 2017-03-08 |
| MA39927B1 MA39927B1 (fr) | 2018-09-28 |
Family
ID=50677958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39927A MA39927B1 (fr) | 2014-04-30 | 2015-04-27 | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9877963B2 (fr) |
| EP (1) | EP3137073B1 (fr) |
| JP (1) | JP6283766B2 (fr) |
| KR (1) | KR101869185B1 (fr) |
| CN (1) | CN106163520B (fr) |
| AR (1) | AR100209A1 (fr) |
| CY (1) | CY1120508T1 (fr) |
| ES (1) | ES2683184T3 (fr) |
| HR (1) | HRP20181205T1 (fr) |
| MA (1) | MA39927B1 (fr) |
| MY (1) | MY189930A (fr) |
| PH (1) | PH12016501784B1 (fr) |
| PT (1) | PT3137073T (fr) |
| RS (1) | RS57535B1 (fr) |
| SG (2) | SG10201909382UA (fr) |
| SI (1) | SI3137073T1 (fr) |
| TR (1) | TR201809598T4 (fr) |
| WO (1) | WO2015165842A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3199156A1 (fr) * | 2016-02-01 | 2017-08-02 | Heinrich-Heine-Universität Düsseldorf | Utilisation d'antagonistes du transporteur de la glycine 1 comme analgésiques du systeme nerveux central |
| CU20200106A7 (es) * | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
| CA3166938A1 (fr) * | 2020-01-09 | 2021-07-15 | Disc Medicine, Inc. | Methodes de traitement de protoporphyrie erythropoietique, de protoporphyrie liee a x ou de porphyrie erythropoietique congenitale avec des inhibiteurs de transport de glycine |
| EP4304597A4 (fr) * | 2021-03-12 | 2025-02-19 | Disc Medicine, Inc. | Compositions et méthodes de traitement de l'anémie associée à un trouble ribosomique |
| JP2024518091A (ja) * | 2021-05-14 | 2024-04-24 | ディスク・メディシン・インコーポレイテッド | グリシン輸送阻害剤を用いて赤血球増殖性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法 |
| JP2024520391A (ja) * | 2021-05-27 | 2024-05-24 | ディスク・メディシン・インコーポレイテッド | ビトペルチンの固体形態を用いて赤血球増殖性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法 |
| WO2023235326A1 (fr) * | 2022-05-31 | 2023-12-07 | Disc Medicine, Inc. | Compositions et méthodes de traitement de porphyries hépatiques avec des inhibiteurs de transport de glycine |
| WO2025059425A1 (fr) * | 2023-09-15 | 2025-03-20 | Disc Medicine, Inc. | Inhibiteurs de glyt-1 et leurs utilisations |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53252B (sr) * | 2003-08-11 | 2014-08-29 | F.Hoffmann-La Roche Ag. | Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1 |
| HRP20100076T1 (hr) * | 2005-02-07 | 2010-03-31 | F. Hoffmann - La Roche Ag | Heterociklički supstituirani fenil metanoni kao inhibitori glicin transportera 1 |
-
2015
- 2015-04-27 JP JP2017505724A patent/JP6283766B2/ja active Active
- 2015-04-27 CN CN201580016721.4A patent/CN106163520B/zh active Active
- 2015-04-27 ES ES15717916.9T patent/ES2683184T3/es active Active
- 2015-04-27 RS RS20180897A patent/RS57535B1/sr unknown
- 2015-04-27 WO PCT/EP2015/059037 patent/WO2015165842A1/fr not_active Ceased
- 2015-04-27 SI SI201530334T patent/SI3137073T1/sl unknown
- 2015-04-27 MY MYPI2016001545A patent/MY189930A/en unknown
- 2015-04-27 HR HRP20181205TT patent/HRP20181205T1/hr unknown
- 2015-04-27 KR KR1020167030222A patent/KR101869185B1/ko active Active
- 2015-04-27 EP EP15717916.9A patent/EP3137073B1/fr active Active
- 2015-04-27 MA MA39927A patent/MA39927B1/fr unknown
- 2015-04-27 SG SG10201909382U patent/SG10201909382UA/en unknown
- 2015-04-27 SG SG11201608397UA patent/SG11201608397UA/en unknown
- 2015-04-27 PT PT157179169T patent/PT3137073T/pt unknown
- 2015-04-27 TR TR2018/09598T patent/TR201809598T4/tr unknown
- 2015-04-28 AR ARP150101268A patent/AR100209A1/es not_active Application Discontinuation
-
2016
- 2016-09-13 PH PH12016501784A patent/PH12016501784B1/en unknown
- 2016-10-26 US US15/334,722 patent/US9877963B2/en active Active
-
2018
- 2018-08-06 CY CY20181100809T patent/CY1120508T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015165842A1 (fr) | 2015-11-05 |
| EP3137073B1 (fr) | 2018-06-06 |
| PT3137073T (pt) | 2018-07-27 |
| TR201809598T4 (tr) | 2018-07-23 |
| CN106163520B (zh) | 2019-12-13 |
| SG11201608397UA (en) | 2016-11-29 |
| CY1120508T1 (el) | 2019-07-10 |
| JP2017511385A (ja) | 2017-04-20 |
| SG10201909382UA (en) | 2019-11-28 |
| MA39927B1 (fr) | 2018-09-28 |
| ES2683184T3 (es) | 2018-09-25 |
| CN106163520A (zh) | 2016-11-23 |
| KR20160130517A (ko) | 2016-11-11 |
| HRP20181205T1 (hr) | 2018-09-21 |
| EP3137073A1 (fr) | 2017-03-08 |
| US9877963B2 (en) | 2018-01-30 |
| SI3137073T1 (sl) | 2018-09-28 |
| RS57535B1 (sr) | 2018-10-31 |
| PH12016501784A1 (en) | 2016-11-07 |
| US20170042888A1 (en) | 2017-02-16 |
| JP6283766B2 (ja) | 2018-02-21 |
| AR100209A1 (es) | 2016-09-21 |
| MY189930A (en) | 2022-03-22 |
| KR101869185B1 (ko) | 2018-06-19 |
| PH12016501784B1 (en) | 2016-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1034I2 (fr) | Composés aryle, hétéroaryle et hétérocycliques pour le traitement de troubles induits par un complément | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| IL253945B (en) | kdm1a inhibitors to treat the disease | |
| EP3328376A4 (fr) | Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique | |
| EP3370703A4 (fr) | Combinaison de gemcabène pour le traitement de maladies cardiovasculaires | |
| EP3313325A4 (fr) | Échafaudages implantables pour le traitement de la sinusite | |
| EP3448398A4 (fr) | Compositions et méthodes pour le traitement de troubles cutanés | |
| MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
| EP3374502A4 (fr) | Procédés pour le traitement de dystrophies cornéennes | |
| EP3340982A4 (fr) | Composés pour le traitement de troubles immunitaires et inflammatoires | |
| PT3119397T (pt) | Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama | |
| MA39753A (fr) | Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues | |
| EP3351189A4 (fr) | Instrument de traitement pour endoscope | |
| EP3288592A4 (fr) | Utilisation de cannabidiol pour le traitement de spasmes infantiles | |
| MA39927A (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
| MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| EP3335041A4 (fr) | Biomarqueurs pour le traitement de la pelade | |
| EP3316887A4 (fr) | Inhibiteurs de gls1 pour le traitement de maladies | |
| MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
| PL3247459T3 (pl) | Urządzenie do działania ultradźwiękami na rany otwarte | |
| EP3334432A4 (fr) | Cerdulatinib pour le traitement du myélome | |
| EP3621434A4 (fr) | Méthodes de traitement de troubles neuropsychiatriques | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| EP3318205A4 (fr) | Instrument de traitement pour endoscope |